Skip to main contentAll experts

MrsShannon Boye

PROF

MD-PEDIATRICS

Orcid identifier0000-0002-7312-3197 (opens in a new tab)⁠
  • PROF
    MD-PEDIATRICS

GRANTS

  • GRANT
    Characterization of ocular phenotype of the YG8-800 mouse model of FA and retinal-targeted treatment by AAV based CRISPR-Cas9 gene editing
    Friedreichs Ataxia Research Alliance5 Mar 2025 - 28 Feb 2027
    Active
  • GRANT
    Development of a New Gene Therapy for Autosomal Dominant Retinitis Pigmentosa
    Foundation for Fighting Blindness1 Jan 2025 - 31 Dec 2026
    Active
  • GRANT
    Mouse model of KIZ
    Foundation for Fighting Blindness25 Sep 2024 - 14 Sep 2025
    Expired
  • GRANT
    Engineering AAV for safe and efficient gene delivery to the human retina
    National Institute of Health Nei5 Sep 2024 - 30 Jun 2029
    Active
  • GRANT
    PDE6A Gene Therapy Agreement
    Stiftung Für Medizininnovationen20 Aug 2024 - 19 Aug 2027
    Active
  • GRANT
    Natural history and AAV-mediated interventions for dominant negative and haploinsufficient mouse models of PRPH2-associated disease
    Foundation for Fighting Blindness1 Apr 2024 - 31 Mar 2027
    Active
  • GRANT
    Nonhuman Primate Model of Inherited Photoreceptor Degeneration
    National Institute of Health Nei5 Feb 2024 - 31 Mar 2026
    Expired
  • GRANT
    Creation of a Translational Nonhuman Primate Model of Usher Syndrome 1B
    Foundation for Fighting Blindness6 Nov 2023 - 31 Mar 2026
    Expired
  • GRANT
    AAV-Mediated Therapy for Visual Impairment associated with Friedreich’s Ataxia
    Friedreichs Ataxia Research Alliance30 Aug 2023 - 31 Aug 2025
    Expired
  • GRANT
    Task Order 17: Evaluation of multiple lots of AAV-hRS1 in Rs1-/- KO mice
    Atsena Therapeutics17 Jul 2023 - 31 Mar 2024
    Expired
  • GRANT
    Maintenance of RS1 Mouse Model#
    Atsena Therapeutics13 Feb 2023 - 30 Jun 2027
    Active
  • GRANT
    Characterization and mitigation of AAV-induced ocular inflamation
    Foundation for Fighting Blindness10 Feb 2023 - 31 Mar 2026
    Expired
  • GRANT
    Task Order #15- Assessment of AAV-GUCY2D vectors in Gucy2e KO mice
    Atsena Therapeutics5 Oct 2022 - 31 Mar 2023
    Expired
  • GRANT
    Maintenance of CNGB3 Mouse Models
    Atsena Therapeutics27 Sep 2022 - 10 Jul 2023
    Expired
  • GRANT
    Task Order #13- ‘Development of AAV Candidates for the Treatment of Ocular Friedrich’s Ataxia’
    Atsena Therapeutics27 Sep 2022 - 10 Jul 2023
    Expired
  • GRANT
    ATSN-AVT-ROD-004: Axon Targeting Motif Identification
    Atsena Therapeutics19 Apr 2022 - 14 Apr 2023
    Expired
  • GRANT
    Assessment of Candidate Vectors for AAV-mediated Delivery of ABCA4
    Atsena Therapeutics15 Apr 2022 - 28 Feb 2027
    Active
  • GRANT
    Achroma Check_Boye
    Achroma Corporation30 Jan 2022 - 30 Apr 2025
    Expired
  • GRANT
    Task Order 10 - ATSN-CAP-RD-02 Lead Capsid Vector Evaluation
    Atsena Therapeutics19 Jan 2022 - 15 Jun 2022
    Expired
  • GRANT
    Propagation of a Nonhuman Primate Model of Usher Syndrome
    Foundation for Fighting Blindness22 Nov 2021 - 31 Aug 2023
    Expired
  • GRANT
    ATSN-CAP-RD-01, P2 Peptide Library Selection
    Atsena Therapeutics17 Nov 2021 - 30 Jun 2023
    Expired
  • GRANT
    Task Order #8 ATSN-201 Vector Bridging Study
    Atsena Therapeutics7 Sep 2021 - 30 Sep 2022
    Expired
  • GRANT
    Task Order #7 - Hybrid Toxicology, Efficacy and Biodistribution (BD) Study in support of an AAV gene therapy for the treatment of XLRS (ATSN-201) following subretinal administration in RS1-/- knockout mic
    Atsena Therapeutics12 May 2021 - 31 Dec 2022
    Expired
  • GRANT
    Vascular Gene Delivery and Early Disease Biomarkers in Diabetic Retinopathy Yr. 3
    National Institute of Health Nei19 Oct 2020 - 31 Aug 2023
    Expired
  • GRANT
    AAV-MEDIATED THERAPY FOR VISUAL IMPAIRMENT ASSOCIATED WITH FRIEDREICH'S ATAXIA
    Friedreichs Ataxia Research Alliance17 Sep 2020 - 30 Sep 2022
    Expired